---
layout: default
title: Ropivacaine
parent: 僅模型預測 (L5)
nav_order: 299
evidence_level: L5
indication_count: 4
---

# Ropivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropivacaine: From Regional Anesthesia to Migraine Disorder

## One-Sentence Summary

Ropivacaine is a long-acting local anesthetic widely used for regional anesthesia, epidural analgesia, and perioperative pain management.
The TxGNN model predicts it may be effective for **Migraine Disorder**,
with **4 clinical trials** and **6 publications** currently supporting this direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Regional anesthesia and perioperative pain management |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L3 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |

---

## Why is This Prediction Reasonable?

Ropivacaine is a long-acting amide-type local anesthetic that works by blocking voltage-gated sodium channels (Nav), thereby inhibiting the generation and conduction of nerve impulses. Although detailed MOA data from DrugBank is currently unavailable, the mechanistic rationale for its use in migraine is well-grounded in known neuroanatomy.

Migraine involves the trigeminovascular system and autonomic dysregulation. Ropivacaine can interrupt this pain circuitry through at least three recognized interventional approaches: (1) **Sphenopalatine Ganglion (SPG) Block** — disrupting parasympathetic input that drives intracranial vasodilation and neurogenic inflammation; (2) **Stellate Ganglion Block (SGB)** — modulating sympathetic hyperactivation associated with migraine chronification; and (3) **Trigger Point Injections** — breaking peripheral sensitization cycles at myofascial trigger points known to maintain migraine attacks.

This is not a purely theoretical prediction. Controlled clinical studies have directly tested ropivacaine trigger point injections for migraine prophylaxis (García-Leiva et al., 2007), and a completed emergency department trial (NCT00680823, n=150) evaluated paraspinal intramuscular ropivacaine specifically for pediatric headache. The TxGNN model's high prediction score (99.65%) likely reflects well-established graph connections between sodium channel blockade and trigeminovascular pain nodes in the knowledge graph — consistent with existing clinical practice.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|-------------|-------|--------|------------|--------------|
| [NCT00680823](https://clinicaltrials.gov/study/NCT00680823) | NA | Completed | 150 | Paraspinal intramuscular ropivacaine injection for pediatric headache in an emergency department setting — the only trial directly testing ropivacaine for headache; largest sample in this dataset |
| [NCT03666663](https://clinicaltrials.gov/study/NCT03666663) | Phase 4 | Completed | 10 | Randomized double-blind placebo-controlled trial of sphenopalatine ganglion (SPG) block using local anesthetics vs. placebo for migraine prevention in adults; rigorous design but severely underpowered (n=10) |
| [NCT05301387](https://clinicaltrials.gov/study/NCT05301387) | N/A | Completed | 38 | Long-term follow-up of sphenopalatine ganglion block for post-dural puncture headache; mechanism highly overlaps with migraine but indication differs — cross-indication analogy only |
| [NCT06470581](https://clinicaltrials.gov/study/NCT06470581) | NA | Not Yet Recruiting | 78 | Thoracic sympathetic ganglion block with botulinum toxin for complex regional pain syndrome — ropivacaine used as comparator local anesthetic; primary drug is botulinum toxin, indirect relevance only |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|--------------|
| [17244105](https://pubmed.ncbi.nlm.nih.gov/17244105/) | 2007 | Controlled Study / Prospective | Pain Medicine | Ropivacaine trigger point injections over 12 weeks for prophylactic management of severe migraine — direct evidence for ropivacaine in migraine prevention |
| [35331152](https://pubmed.ncbi.nlm.nih.gov/35331152/) | 2022 | Prospective Observational | BMC Anesthesiology | Ultrasound-guided stellate ganglion block effectively relieved migraine pain and improved quality of life — supports sympathetic modulation pathway |
| [30043973](https://pubmed.ncbi.nlm.nih.gov/30043973/) | 2019 | Cohort / Interventional | Headache | Regional anesthetic SPG block reduced self-reported pain in status migrainosus (attacks >72 hours); SPG plays critical role in migraine pain propagation |
| [24284858](https://pubmed.ncbi.nlm.nih.gov/24284858/) | 2013 | Case Series / Pilot | Pain Physician | Novel transnasal topical SPG block technique described for headache and facial pain conditions — procedural refinement supporting SPG as a target |
| [19145569](https://pubmed.ncbi.nlm.nih.gov/19145569/) | 2009 | Case Report | Revista de Neurologia | Horner's syndrome following epidural analgesia — safety signal relevant to sympathetic chain involvement during regional nerve blocks |
| [17058040](https://pubmed.ncbi.nlm.nih.gov/17058040/) | 2006 | Case Report | The Journal of Headache and Pain | Migraine headache as a rare complication after cervicothoracic block — highlights bidirectional relationship between regional blocks and migraine neurology |

---

## Philippines Market Information

Ropivacaine is currently **not registered** with the Philippine FDA. There are no active product licenses on record. This means no locally approved product label, dosage form, or indication data is available from Philippine regulatory sources.

---

## Safety Considerations

Please refer to the package insert for safety information. Philippine FDA package insert data and TFDA labeling warnings/contraindications are not yet available in the current evidence pack (Data Gap). Drug-drug interaction data returned no results in the current query.

> **Note for clinical teams:** Before any clinical application, full prescribing information from the originator (AstraZeneca/Fresenius Kabi) should be reviewed, particularly regarding: cardiovascular toxicity risk (QRS widening, ventricular arrhythmia), CNS toxicity (seizures at high plasma concentrations), use in patients with hepatic impairment, and maximum dose limits for regional nerve blocks.

---

## Conclusion and Next Steps

**Decision: Proceed with Guardrails**

**Rationale:**
Evidence from a completed 150-patient emergency department trial and a prospective controlled study using ropivacaine trigger point injections for severe migraine establishes a meaningful clinical signal beyond model prediction alone; the mechanistic rationale (sodium channel blockade of trigeminovascular and autonomic pathways) is biologically coherent and supported by multiple interventional approaches already used in headache medicine.

**To proceed, the following is needed:**

- **Regulatory pathway**: Ropivacaine is not registered in the Philippines — a product registration application or compassionate use protocol would be required before any clinical use
- **MOA data**: Retrieve full DrugBank mechanism-of-action entry (DB00296) to complete the mechanistic analysis
- **Safety package**: Download and parse the originator package insert (Naropin®) for full warnings, contraindications, and drug interaction data
- **Confirmatory RCT design**: The key evidence gap is the absence of a Phase 2/3 RCT specifically for ropivacaine in migraine — the best available direct trial (NCT00680823) is Phase NA in a pediatric ED setting; an adequately powered adult RCT for prophylactic or acute migraine treatment would be needed for L2 upgrade
- **Route-of-administration specification**: Clarify which delivery route (trigger point injection, SPG block, or intramuscular) is most feasible in the Philippines healthcare context, as each requires different procedural infrastructure
- **Pediatric vs. adult stratification**: NCT00680823 was conducted in a pediatric population; adult efficacy data specifically for ropivacaine in migraine remains limited and should be evaluated separately
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

